# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

> **NCT02987972** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1051 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** V114 Lot 1
- **BIOLOGICAL:** V114 Lot 2
- **BIOLOGICAL:** Prevnar 13™

## Key facts

- **NCT ID:** NCT02987972
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-21
- **Primary completion:** 2018-10-04
- **Final completion:** 2018-10-04
- **Target enrollment:** 1051 (ACTUAL)
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987972, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02987972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*